Genetics determine optimal drug dose of common anticoagulant

Aug 21, 2007

Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood, the journal of the American Society of Hematology. This result represents one of the first applications of using an individual’s genetic information to guide personal medical care.

Because individuals metabolize drugs differently, varying doses of warfarin are needed for the drug to be effective in each patient. Too much warfarin can cause severe bleeding, and too little can cause dangerous blood clots. Currently, there is little guidance for predicting how much of the drug a person will need. Physicians have had to roughly estimate an initial dose of warfarin and then continually monitor a patient’s International Normalized Ratio (INR) value (a measure of how fast the blood clots), during treatment to tweak the dosage by trial and error.

For the first time, a group of St. Louis researchers combined the standard INR method with genetic testing to predict the therapeutic warfarin dose. Since warfarin is often prescribed after major orthopedic surgery to prevent blood clots in the legs, the study followed 92 adults undergoing either total hip or knee replacement at the Washington University Medical Center, who had never previously taken the anticoagulant.

Prior to warfarin treatment, the researchers collected blood samples and each patient’s medical history. The blood tests were used to examine variations in two genes, CYP2C9 and VKORC1, that may affect warfarin dosing. Variants in CYP2C9 impair the body’s breakdown of warfarin; variants in VKORC1 cause increased warfarin sensitivity. The patients were assigned initial doses of warfarin based on clinical factors and their genotype. The researchers followed the patients until successful treatment outcomes were achieved several weeks later.

By combining variants in these genes with initial INR response and other clinical factors, the researchers derived a dosing equation that estimated the therapeutic warfarin dose. The researchers found that these two genes were important in predicting the response to warfarin. Additional factors, such as blood loss during surgery and smoking status, also correlated with therapeutic dose.

Using these data, the researchers developed a therapeutic model that could be used by physicians to refine warfarin dosage with greater accuracy than clinical factors alone. The researchers have made this dosing model publicly available on a free Web site, www.warfarindosing.org, and are now validating it in orthopedic and non-orthopedic patients beginning warfarin therapy.

If validated, particularly in patients taking warfarin for reasons other than orthopedic surgery, such as to prevent stroke, this gene-based dosing could predict a safe and effective warfarin dose at the start of treatment, thus minimizing the risks of the current trial-and-error approach.

Source: American Society of Hematology

Explore further: Hidden gene gives hope for improving brain function

add to favorites email to friend print save as pdf

Related Stories

Driverless shuttle will be on the move in UK

27 minutes ago

(Phys.org) —"Autonomous public transport" is on the minds of planners who envision self-driving vehicles that would cross over short distances, suited for airport transport, industrial sites, theme parks ...

Superfish points fingers over ad software security flaws

2 hours ago

A little-known Silicon Valley startup was caught in a firestorm of criticism this week for making software that exposed Lenovo laptop users to hackers bent on stealing personal information. But Superfish Inc. ...

Huge spring tides draw crowds to French Atlantic coast

21 hours ago

France kicked off nearly a month of exceptionally large spring tides Saturday, as tourists flocked to coastal areas to witness spectacularly high water levels ahead of the so-called "tide of the century" ...

Water in Oregon pipeline is tapped for electricity

23 hours ago

Lucid Energy has developed a renewable energy system that makes use of water moving through pipelines. The company's LucidPipe Power System converts pressure in water pipelines into electricity. They have ...

Recommended for you

Exploring the genetic origins of autism

Feb 25, 2015

The geneticist Sébastien Jacquemont is the new holder of the Canada Research Chair in Genetics of Neurodevelopmental Disorders and Associated Dysregulation in Energy Balance at the University of Montreal. He moved to the ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.